Article
Supporting Information Available: Elemental analysis and
high-resolution mass spectra (HRMS) (ESI). This material is
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 3 1317
High Affinity Folate Receptors over the Reduced Folate Carrier
and Proton-Coupled Folate Transporter for Cellular Entry.
J. Med. Chem. 2009, 52, 2940–2951.
(19) Jansen, G. Receptor- and Carrier-Mediated Transport Systems for
Folates and Antifolates: Exploitation for Folate Chemotherapy
and Immunotherapy. In Anticancer Development Guide: Antifolate
Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press Inc.:
Totowa, NJ, 1999; pp 293-321.
(20) Jones, T. R.; Calvert, A. H.; Jackman, A. L.; Eakin, M. A.;
Smithers, M. J.; Betteridge, R. F.; Newell, D. R.; Hayter, A. J.;
Stocker, A.; Harland, S. J.; et al. Quinazoline Antifolates Inhi-
biting Thymidylate Synthase: Variation of the N10 Substituent.
J. Med. Chem. 1985, 28, 1468–1476.
(21) Jones, T. R.; Calvert, A. H.; Jackman, A. L.; Brown, S. J.; Jones,
M.; Harrap, K. R. A Potent Antitumour Quinazoline Inhibitor
of Thymidylate Synthetase: Synthesis, Biological Properties
and Therapeutic Results in Mice. Eur. J. Cancer 1981, 17,
11–19.
(22) Theti, D. S.; Bavetsias, V.; Skelton, L. A.; Titley, J.; Gibbs, D.;
Jansen, G.; Jackman, A. L. Selective Delivery of CB300638, A
Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor
into Human Tumor Cell Lines Overexpressing the Alpha-Isoform
of the Folate Receptor. Cancer Res. 2003, 63, 3612–3618.
(23) Gibbs, D. D.; Theti, D. S.; Wood, N.; Green, M.; Raynaud, F.;
Valenti, M.; Forster, M. D.; Mitchell, F.; Bavetsias, V.; Henderson,
E.; Jackman, A. L. BGC 945, A Novel Tumor-Selective Thymidy-
late Synthase Inhibitor Targeted to Alpha-Folate Receptor-Over-
expressing Tumors. Cancer Res. 2005, 65, 11721–11728.
(24) Kugel Desmoulin, S.; Wang, Y.; Wu, J.; Hou, Z.; Cherian, C.;
Gangjee, A.; Matherly, L. H. Discovery of a Glycinamide Ribo-
nucleotide Formyltransferase Inhibitor with Solid Tumor Selecti-
vity via Its Transport by the Proton-Coupled Folate Transporter.
Abstr., Am. Assoc. Cancer Res. 2009, 50, 404.
References
(1) Monahan, B. P.; Allegra, C. J. Antifolates. In Cancer Chemother-
apy and Biotherapy, 4th ed.; Chabner, B. A., Longo, D. L., Eds.;
Lippincott-Raven: Philadelphia, 2001; pp 109-148.
(2) Hazarika, M.; White, R. M.; Johnson, J. R.; Pazdur, R. FDA Drug
Approval Summaries: Pemetrexed (Alimta). Oncologist 2004, 9,
482–488.
(3) Scagliotti, G. V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteen-
kiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.;
Digumarti, R.; Zukin, M.; Lee, J. S.; Mellemgaard, A.; Park, K.;
Patil, S.; Rolski, J.; Goksel, T.; de Marinis, F.; Simms, L.;
Sugarman, K. P.; Gandara, D. Phase III Study Comparing Cis-
platin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemo-
therapy-Naive Patients with Advanced-Stage Non-Small-Cell
Lung Cancer. J. Clin. Oncol. 2008, 26, 3543–3551.
(4) Ciuleanu, T.; Brodowicz, T.; Zielinski, C; Kim, J. H.; Krzakowski,
M.; Laack, E.; Wu, Y. L.; Bover, I.; Begbie, S.; Tzekova, V.;
Cucevic, B.; Pereira, J. R.; Yang, S. H.; Madhavan, J.; Sugarman,
K. P.; Peterson, P.; John, W. J.; Krejcy, K.; Belani, C. P. Main-
tenance Pemetrexed Plus Best Supportive Care versus Placebo Plus
Best Supportive Care for Non-Small-Cell Lung Cancer: A Rando-
mised, Double-Blind, Phase 3 Study. Lancet 2009, 374, 1432–1440.
(5) Chu, E.; Callender, M. A.; Farrell, M. P.; Schmitz, J. C. Thymidy-
late Synthase Inhibitors as Anticancer Agents: From Bench
to Bedside. Cancer Chemother. Pharmacol. 2003, 52 (Suppl. 1),
S80–89.
(6) Matherly, L. H.; Goldman, I. D. Membrane Transport of Folates.
(25) Wang, L.; Kugel Desmoulin, S.; Deng, Y.; Polin, L.; Cherian, C.;
Matherly, L. H.; Gangjee, A. The Design, Synthesis and in Vitro
and in Vivo Evaluation of Selective FR R and β and PCFT
Substrates with Potent GARFTase Inhibitory Activity as Anti-
tumor Agents. Abstr., Am. Assoc. Cancer Res. 2009, 50, 463.
(26) Ray, M. S.; Muggia, F. M.; Leichman, G.; Grunberg, S. M.;
Nelson, R. L.; Dyke, R. W.; Moran, R. G. Phase I Study of
(6R)-5,10-Dideazatetrahydrofolate: A Folate Antimetabolite In-
hibitory to De Novo Purine Synthesis. J. Natl. Cancer Inst. 1993,
85, 1154–1159. Cole, J. T.; Gralla, R. J.; Kardinal, C. G.; Rivera, N. P.
Lometrexol (DDATHF): Phase I Trial of a Weekly Schedule of This
New Antifolate. Proc. Am. Assoc. Cancer Res. 1992, 33, 2468.
Wedge, S. R.; Laohavinij, S.; Taylor, G. A.; Newell, D. R.; Charlton,
C. J.; Proctor, M.; Chapman, R.; Simmons, D.; Oakey, A.; Gumbrell, L.;
Calvert, A. H. Proc. Am. Assoc. Cancer Res. 1993, 34, 1629.
(27) Budman, D. R.; Johnson, R.; Barile, B.; Bowsher, R. R.;
Vinciguerra, V.; Allen, S. L.; Kolitz, J.; Ernest, C. S., II; Kreis,
W.; Zervos, P.; Walling, J. Phase I and Pharmacokinetic Study of
LY309887: A Specific Inhibitor of Purine Biosynthesis. Cancer
Chemother. Pharmacol. 2001, 47, 525–531.
(28) Boritzki, T. J.; Zhang, C.; Bartlett, C. A.; Jackson, R. C. AG2034 A
GARFT Inhibitor With Selective Cytotoxicity to Cells that Lack a
G1 Checkpoint. In Anticancer Drug Development Guide: Antifolate
Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press Inc.:
Totowa, NJ, 1999; pp 281-292.
(29) McLeod, H. L.; Cassidy, J.; Powrie, R. H.; Priest, D. G.; Zorbas,
M. A.; Synold, T. W.; Shibata, S.; Spicer, D.; Bissett, D.; Pithavala,
Y. K.; Collier, M. A.; Paradiso, L. J.; Roberts, J. D. Pharmaco-
kinetic and Pharmacodynamic Evaluation of the Clycinamide
Ribonucleotide Formyltransferase Inhibitor AG2034. Clin.
Cancer. Res. 2000, 6, 2677–2684.
Vitam. Horm. 2003, 66, 403–456.
(7) Matherly, L. H.; Hou, Z.; Deng, Y. Human Reduced Folate
Carrier: Translation of Basic Biology to Cancer Etiology and
Therapy. Cancer Metastasis Rev. 2007, 26, 111–128.
(8) Zhao, R.; Matherly, L. H.; Goldman, I. D. Membrane Transpor-
ters and Folate Homeostasis; Intestinal Absorption, Transport
into Systemic Compartments and Tissues. Expert Rev. Mol. Med.
2009, 11, No. e4.
(9) Salazar, M. D.; Ratnam, M. The Folate Receptor: What Does It
Promise in Tissue-Targeted Therapeutics? Cancer Metastasis Rev.
2007, 26, 141–152.
(10) Elnakat, H.; Ratnam, M. Distribution, Functionality and Gene
Regulation of Folate Receptor Isoforms: Implications in Targeted
Therapy. Adv. Drug Delivery 2004, 56, 1067–1084.
(11) Qiu, A.; Jansen, M.; Sakaris, A.; Min, S. H.; Chattopadhyay, S;
Tsai, E.; Sandoval, C.; Zhao, R; Akabas, M. H.; Goldman, I. D.
Identification of an Intestinal Folate Transporter and the Molec-
ular Basis for Hereditary Folate Malabsorption. Cell 2006, 127,
917–928.
(12) Zhao, R.; Goldman, I. D. The Molecular Identity and Characteri-
zation of a Proton-Coupled Folate Transporter-PCFT; Biological
Ramifications and Impact on the Activity of Pemetrexed. Cancer
Metastasis Rev. 2007, 26, 129–139.
(13) Reddy, J. A.; Haneline, L. S.; Srour, E. F.; Antony, A. C.; Clapp,
D. W.; Low, P. S. Expression and Functional Characterization of
the Beta-Isoform of the Folate Receptor on CD34(þ) Cells. Blood
1999, 93, 3940–3948.
(14) Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; Westrick, E.; Dawson,
A.; Dorton, R.; Vetzel, M.; Santhapuram, H. K.; Wang, Y.
Preclinical Antitumor Activity of a Novel Folate-Targeted Dual
Drug Conjugate. Mol. Pharmaceutics 2007, 4, 659–667.
(15) Lu, Y.; Wu, J.; Gonit, M.; Yang, X.; Lee, A.; Xiang, G.; Li, H.; Liu,
S.; Marcucci, G.; Ratnam, M.; Lee, R. J. Role of Formulation
Composition in Folate Receptor-Targeted Liposomal Doxoru-
bicin Delivery to Acute Myelogenous Leukemia Cells. Mol.
Pharmaceutics 2007, 4, 707–712.
(30) Wong, S. C.; Proefke, S. A.; Bhushan, A.; Matherly, L. H. Isolation
of Human cDNAs that Restore Methotrexate Sensitivity and
Reduced Folate Carrier Activity in Methotrexate Transport-
Defective Chinese Hamster Ovary Cells. J. Biol. Chem. 1995, 270,
17468–17475.
(31) Flintoff, W. F.; Davidson, S. V.; Siminovitch, L. Isolation and
Partial Characterization of Three Methotrexate-Resistant Pheno-
types from Chinese Hamster Ovary Cells. Som. Cell Genet. 1976, 2,
245–261.
(16) Muller, C.; Forrer, F.; Schibli, R.; Krenning, E. P.; de Jong, M.
SPECT Study of Folate Receptor-Positive Malignant and Normal
Tissues in Mice Using a Novel 99mTc-Radiofolate. J. Nucl. Med.
2008, 49, 310–317.
(32) Beardsley, G. P.; Moroson, B. A.; Taylor, E. C.; Moran, R. G. A
New Folate Antimetabolite, 5,10-Dideaza-5,6,7,8-tetrahydrofo-
late is a Potent Inhibitor of de novo purine Synthesis. J. Biol.
Chem. 1989, 264, 328–333.
(33) Shih, C.; Thornton, D. E. Preclinical Pharmacology Studies on the
Clinical Development of a Novel Multitargeted Antifolate, MTA
(LY231514). In Anticancer Development Guide: Antifolate Drugs in
Cancer Therapy; Jackman, A. L., Ed.; Humana Press Inc.: Totowa, NJ,
1999; pp 183-201.
(17) Deng, Y.; Wang, Y.; Cherian, C.; Hou, Z.; Buck, S. A.; Matherly,
L. H.; Gangjee, A. Synthesis and Discovery of High Affinity Folate
Receptor-Specific Glycinamide Ribonucleotide Formyltransferase
Inhibitors with Antitumor Activity. J. Med. Chem. 2008, 51, 5052–
5063.
(18) Deng, Y.; Zhou, X.; Kugel Desmoulin, S.; Wu, J.; Cherian, C.;
Hou, Z.; Matherly, L. H.; Gangjee, A. Synthesis and Biological
Activity of a Novel Series of 6-Substituted Thieno[2,3-d]pyrimidine
Antifolate Inhibitors of Purine Biosynthesis with Selectivity for